These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38985794)

  • 1. Tailoring neoadjuvant systemic therapy in breast cancer: "The advent of a personalized approach"-The Breast-Gynecological and Immuno-Oncology International Cancer Conference (BGICC) consensus and recommendations.
    Elghazaly H; Azim HA; Rugo HS; Cameron D; Swain SM; Curigliano G; Harbeck N; Tripathy D; Arun B; Aapro M; Piccart M; Cardoso F; Gligorov J; Elghazawy H; El Saghir NS; Penault-Llorca F; Perez EA; Poortmans P; Abdelaziz H; El-Zawahry HM; Kassem L; Sabry M; Viale G; Al-Sukhun S; Gado N; Leung JWT; Ezz Elarab L; Cardoso MJ; Abdel Karim K; Foheidi M; Elmaadawy MM; Conte P; Selim ASM; Kandil A; Kamal RM; Paltuev RM; Guarneri V; Abulkhair O; Zakaria O; Golshan M; Orecchia R; ElMahdy M; Abdel-Aziz AM; Eldin NB
    Cancer; 2024 Oct; 130(19):3251-3271. PubMed ID: 38985794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer.
    Elghazaly H; Rugo HS; Azim HA; Swain SM; Arun B; Aapro M; Perez EA; Anderson BO; Penault-Llorca F; Conte P; El Saghir NS; Yip CH; Ghosn M; Poortmans P; Shehata MA; Giuliano AE; Leung JWT; Guarneri V; Gligorov J; Gulluoglu BM; Abdel Aziz H; Frolova M; Sabry M; Balch CM; Orecchia R; El-Zawahry HM; Al-Sukhun S; Abdel Karim K; Kandil A; Paltuev RM; Foheidi M; El-Shinawi M; ElMahdy M; Abulkhair O; Yang W; Aref AT; Bakkach J; Bahie Eldin N; Elghazawy H
    Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34066769
    [No Abstract]   [Full Text] [Related]  

  • 3. A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles.
    Gandhi S; Brackstone M; Hong NJL; Grenier D; Donovan E; Lu FI; Skarpathiotakis M; Lee J; Boileau JF; Perera F; Simmons C; Joy AA; Tran WT;
    Breast Cancer Res Treat; 2022 May; 193(1):1-20. PubMed ID: 35224713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The first BGICC consensus and recommendations for breast cancer awareness, early detection and risk reduction in low- and middle-income countries and the MENA region.
    Elghazaly H; Aref AT; Anderson BO; Arun B; Yip CH; Abdelaziz H; Ghosn M; Al-Foheidi M; Cardenosa G; Leung JWT; Gado N; Balch CM; Sabry M; Ezz Elarab L; Giuliano AE; El-Zawahry HM; Abdel Karim K; Nasr A; Maki H; Chung H; Saadeddin A; Abdelwahab MM; Al Tahan FM; Chalabi N; Frolova M; Kamal RM; Shehata MA; Bahie Eldin N; Elghazawy H
    Int J Cancer; 2021 Aug; 149(3):505-513. PubMed ID: 33559295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptation of international coronavirus disease 2019 and breast cancer guidelines to local context.
    Valencia GA; Neciosup S; Gómez HL; Benites MDP; Falcón S; Moron D; Veliz K; Maldonado M; Auqui R
    World J Clin Oncol; 2021 Jan; 12(1):31-42. PubMed ID: 33552937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
    Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
    J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer.
    Pierre ME; Manneh R; Hernández A; Rodríguez J; Fletcher AV; Ramírez HM; Niño OM; Gómez DA; Sanabria D; Contreras F; Pieschacón JR; Calderón PH
    Rev Colomb Obstet Ginecol; 2024 Jun; 75(1):. PubMed ID: 39013199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.
    Goldhirsch A; Winer EP; Coates AS; Gelber RD; Piccart-Gebhart M; Thürlimann B; Senn HJ;
    Ann Oncol; 2013 Sep; 24(9):2206-23. PubMed ID: 23917950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.
    Eifel P; Axelson JA; Costa J; Crowley J; Curran WJ; Deshler A; Fulton S; Hendricks CB; Kemeny M; Kornblith AB; Louis TA; Markman M; Mayer R; Roter D
    J Natl Cancer Inst; 2001 Jul; 93(13):979-89. PubMed ID: 11438563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic Therapy Advances for HER2-Positive and Triple Negative Breast Cancer: What the Surgeon Needs to Know.
    Downs-Canner S; Weiss A
    Clin Breast Cancer; 2024 Jun; 24(4):328-336. PubMed ID: 38616443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging strategies in neoadjuvant treatment of patients with HER2-positive early breast cancer.
    Harbeck N
    Breast; 2019 Nov; 48 Suppl 1():S97-S102. PubMed ID: 31839172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.
    National Institutes of Health Consensus Development Panel
    J Natl Cancer Inst Monogr; 2001; (30):5-15. PubMed ID: 11773285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant therapy for breast cancer treatment: an expert panel recommendation from the Brazilian Society of Breast Surgeons 2018.
    Barbosa C Rocha F; Falcone AB; Buzaid AC; Pimenta JM; Schvartsman G; Frasson AL
    Breast Cancer Res Treat; 2018 Nov; 172(2):265-272. PubMed ID: 30099633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).
    Amoroso V; Generali D; Buchholz T; Cristofanilli M; Pedersini R; Curigliano G; Daidone MG; Di Cosimo S; Dowsett M; Fox S; Harris AL; Makris A; Vassalli L; Ravelli A; Cappelletti MR; Hatzis C; Hudis CA; Pedrazzoli P; Sapino A; Semiglazov V; Von Minckwitz G; Simoncini EL; Jacobs MA; Barry P; Kühn T; Darby S; Hermelink K; Symmans F; Gennari A; Schiavon G; Dogliotti L; Berruti A; Bottini A
    J Natl Cancer Inst Monogr; 2015 May; 2015(51):90-6. PubMed ID: 26063896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
    Curigliano G; Burstein HJ; Winer EP; Gnant M; Dubsky P; Loibl S; Colleoni M; Regan MM; Piccart-Gebhart M; Senn HJ; Thürlimann B; ; André F; Baselga J; Bergh J; Bonnefoi H; Brucker SY; Cardoso F; Carey L; Ciruelos E; Cuzick J; Denkert C; Di Leo A; Ejlertsen B; Francis P; Galimberti V; Garber J; Gulluoglu B; Goodwin P; Harbeck N; Hayes DF; Huang CS; Huober J; Hussein K; Jassem J; Jiang Z; Karlsson P; Morrow M; Orecchia R; Osborne KC; Pagani O; Partridge AH; Pritchard K; Ro J; Rutgers EJT; Sedlmayer F; Semiglazov V; Shao Z; Smith I; Toi M; Tutt A; Viale G; Watanabe T; Whelan TJ; Xu B
    Ann Oncol; 2017 Aug; 28(8):1700-1712. PubMed ID: 28838210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019).
    Lüftner D; Bauerfeind I; Braun M; Brucker SY; Fasching PA; Felberbaum R; Hagemann F; Haidinger R; Harbeck N; Hönig A; Huober J; Jackisch C; Kolberg HC; Kolberg-Liedtke C; Kühn T; Maass N; Reimer T; Schneeweiss A; Schumacher-Wulf E; Schütz F; Thomssen C; Untch M; Wuerstlein R; Thill M
    Breast Care (Basel); 2019 Oct; 14(5):315-324. PubMed ID: 31798392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial.
    Hofmann D; Nitz U; Gluz O; Kates RE; Schinkoethe T; Staib P; Harbeck N
    Trials; 2013 Aug; 14():261. PubMed ID: 23958221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of Experts.
    Thomssen C; Lüftner D; Untch M; Haidinger R; Würstlein R; Harbeck N; Augustin D; Briest S; Ettl J; Fasching PA; Förster F; Kurbacher CM; Lück HJ; Marschner N; Müller L; Müller V; Perlova-Griff L; Radke I; Ruckhäberle E; Scheffen I; Schumacher-Wulf E; Schwoerer M; Steinfeld-Birg D; Ziegler-Löhr K
    Breast Care (Basel); 2020 Feb; 15(1):82-95. PubMed ID: 32231503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox.
    Dubsky P; Pinker K; Cardoso F; Montagna G; Ritter M; Denkert C; Rubio IT; de Azambuja E; Curigliano G; Gentilini O; Gnant M; Günthert A; Hauser N; Heil J; Knauer M; Knotek-Roggenbauerc M; Knox S; Kovacs T; Kuerer HM; Loibl S; Mannhart M; Meattini I; Penault-Llorca F; Radosevic-Robin N; Sager P; Španić T; Steyerova P; Tausch C; Peeters MTFDV; Weber WP; Cardoso MJ; Poortmans P
    Lancet Oncol; 2021 Jan; 22(1):e18-e28. PubMed ID: 33387500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2- breast cancer: Available evidence and clinical implications.
    Griguolo G; Bottosso M; Vernaci G; Miglietta F; Dieci MV; Guarneri V
    Cancer Treat Rev; 2022 Jan; 102():102323. PubMed ID: 34896969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.